Even though high-dose chemotherapy followed by autologous stem cell support has proven superior to conventional treatment, relapse occurs in approximately 75% of patients within five years after autologous transplantation. Initiating salvage treatment after high-dose therapy may be a reasonnable approach with survival time from relapse being more than two years as documented recently. Reported ...

The lack of robust radiobiological data hampers the further optimization emerging 177Lu-PSMA-directed radioligand therapy (RLT). This study aims to explore several conventional parameters in assessment outcomes tumor and normal organs at risk (OARs) for castration-resistant prostate cancer (CRPC) patients. 20 patients received a median 3 (range 1–6, totally 86 cycles) 177Lu-PSMA-617 RLT were re...

Abstract A simple sublimation technology for the lutetium and ytterbium separation was proposed, which already at stage of preliminary experiments showed effectiveness: (a) completeness Yb resulted in short-term thermal annealing is least 98%, distilled product completely free from 177 Lu, no additional preparation repeated irradiation required ; (b) traditional ion-exchange chromatography can ...

Introduction One of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. Metastatic bone disease is the most common form of malignant bone tumors. Samarium-153-ethylene diamine tetramethylene phosphonate (153Sm-EDTMP) as a radiopharmaceutical is used for pain palliation. This radiopharmaceutical usually emits beta particles, which...

Theranostics is an acronym, which exemplifies the togetherness of diagnostics and therapeutics in the individualized management of disease. The key to personalized medicine in cancer is to determine the molecular phenotypes of neoplasms, so that specific probes can be selected to target the tumor and its microenvironment. Molecular imaging and radionuclide therapy using a particular probe is ba...

Theranostic RIT in CRC Researchers from Memorial Sloan– Kettering Cancer Center (New York, NY) and the Massachusetts Institute of Technology (Cambridge, MA) reported on continuing small animal studies with curative theranostic pretargeted 177LuDOTAT-Bn radioimmunotherapy (PRIT) in GPA33-expressing colorectal cancer. Mice with established SW1222 subcutaneous xenografts underwent treatment with 1...